TP53 and endometrial endometrioid adenocarcinoma: Previous studies have shown that mutant ARID1A and TP53 are mutually exclusive in a variety of cancers, including ovarian clear cells, uterine endometrioid carcinomas, and gastric, breast, and esophageal cancers [27].